Reovirus

A targeted therapeutic - Progress and potential

Radhashree Maitra, Mohammad H. Ghalib, Sanjay Goel

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Medical therapy of patients with malignancy requires a paradigm shift through development of new drugs with a good safety record and novel mechanisms of activity. While there is no dearth of such molecules, one particular agent, "reovirus" is promising by its ability to target cancer cells with aberrant signaling pathways. This double-stranded RNA virus has been therapeutically formulated and has rapidly progressed from preclinical validation of anticancer activity to a phase III registration study in platinum refractory metastatic squamous cell carcinoma of the head and neck. During this process, reovirus has shown safety both as a single agent when administered intratumorally and intravenously, as well as in combination therapy, with multiple chemotherapeutics such as gemcitabine, carboplatin/paclitaxel, and docetaxel; and similarly with radiation. The scientific rationale for its development as an anticancer agent stems from the fact that it preferentially replicates in and induces lyses of cells with an activated Kras pathway. As documented in many previous studies, the initial observation of greater tropism in Kras-compromised situation might certainly not be the sole and possibly not even the predominant reason for enhanced virulence. All the same, scientists have emphasized on Kras optimistically due to its high prevalence in various types of cancers. Incidence of Kras mutation has been found to be highest in pancreatic cancer (85%-90%) followed by colorectal (35-45%) and lung (25-30%). Reovirus, in fact has the potential not only as a therapy but also as a tool to unravel the aberrant cellular pathway leading to carcinogenicity.

Original languageEnglish (US)
Pages (from-to)1514-1525
Number of pages12
JournalMolecular Cancer Research
Volume10
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

docetaxel
gemcitabine
Safety
Neoplasms
Tropism
Double-Stranded RNA
RNA Viruses
Carboplatin
Paclitaxel
Platinum
Pancreatic Neoplasms
Antineoplastic Agents
Virulence
Therapeutics
Observation
Radiation
Lung
Mutation
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

Reovirus : A targeted therapeutic - Progress and potential. / Maitra, Radhashree; Ghalib, Mohammad H.; Goel, Sanjay.

In: Molecular Cancer Research, Vol. 10, No. 12, 12.2012, p. 1514-1525.

Research output: Contribution to journalArticle

@article{e75ed887d83d4573a916ffa2cf3ce3e1,
title = "Reovirus: A targeted therapeutic - Progress and potential",
abstract = "Medical therapy of patients with malignancy requires a paradigm shift through development of new drugs with a good safety record and novel mechanisms of activity. While there is no dearth of such molecules, one particular agent, {"}reovirus{"} is promising by its ability to target cancer cells with aberrant signaling pathways. This double-stranded RNA virus has been therapeutically formulated and has rapidly progressed from preclinical validation of anticancer activity to a phase III registration study in platinum refractory metastatic squamous cell carcinoma of the head and neck. During this process, reovirus has shown safety both as a single agent when administered intratumorally and intravenously, as well as in combination therapy, with multiple chemotherapeutics such as gemcitabine, carboplatin/paclitaxel, and docetaxel; and similarly with radiation. The scientific rationale for its development as an anticancer agent stems from the fact that it preferentially replicates in and induces lyses of cells with an activated Kras pathway. As documented in many previous studies, the initial observation of greater tropism in Kras-compromised situation might certainly not be the sole and possibly not even the predominant reason for enhanced virulence. All the same, scientists have emphasized on Kras optimistically due to its high prevalence in various types of cancers. Incidence of Kras mutation has been found to be highest in pancreatic cancer (85{\%}-90{\%}) followed by colorectal (35-45{\%}) and lung (25-30{\%}). Reovirus, in fact has the potential not only as a therapy but also as a tool to unravel the aberrant cellular pathway leading to carcinogenicity.",
author = "Radhashree Maitra and Ghalib, {Mohammad H.} and Sanjay Goel",
year = "2012",
month = "12",
doi = "10.1158/1541-7786.MCR-12-0157",
language = "English (US)",
volume = "10",
pages = "1514--1525",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Reovirus

T2 - A targeted therapeutic - Progress and potential

AU - Maitra, Radhashree

AU - Ghalib, Mohammad H.

AU - Goel, Sanjay

PY - 2012/12

Y1 - 2012/12

N2 - Medical therapy of patients with malignancy requires a paradigm shift through development of new drugs with a good safety record and novel mechanisms of activity. While there is no dearth of such molecules, one particular agent, "reovirus" is promising by its ability to target cancer cells with aberrant signaling pathways. This double-stranded RNA virus has been therapeutically formulated and has rapidly progressed from preclinical validation of anticancer activity to a phase III registration study in platinum refractory metastatic squamous cell carcinoma of the head and neck. During this process, reovirus has shown safety both as a single agent when administered intratumorally and intravenously, as well as in combination therapy, with multiple chemotherapeutics such as gemcitabine, carboplatin/paclitaxel, and docetaxel; and similarly with radiation. The scientific rationale for its development as an anticancer agent stems from the fact that it preferentially replicates in and induces lyses of cells with an activated Kras pathway. As documented in many previous studies, the initial observation of greater tropism in Kras-compromised situation might certainly not be the sole and possibly not even the predominant reason for enhanced virulence. All the same, scientists have emphasized on Kras optimistically due to its high prevalence in various types of cancers. Incidence of Kras mutation has been found to be highest in pancreatic cancer (85%-90%) followed by colorectal (35-45%) and lung (25-30%). Reovirus, in fact has the potential not only as a therapy but also as a tool to unravel the aberrant cellular pathway leading to carcinogenicity.

AB - Medical therapy of patients with malignancy requires a paradigm shift through development of new drugs with a good safety record and novel mechanisms of activity. While there is no dearth of such molecules, one particular agent, "reovirus" is promising by its ability to target cancer cells with aberrant signaling pathways. This double-stranded RNA virus has been therapeutically formulated and has rapidly progressed from preclinical validation of anticancer activity to a phase III registration study in platinum refractory metastatic squamous cell carcinoma of the head and neck. During this process, reovirus has shown safety both as a single agent when administered intratumorally and intravenously, as well as in combination therapy, with multiple chemotherapeutics such as gemcitabine, carboplatin/paclitaxel, and docetaxel; and similarly with radiation. The scientific rationale for its development as an anticancer agent stems from the fact that it preferentially replicates in and induces lyses of cells with an activated Kras pathway. As documented in many previous studies, the initial observation of greater tropism in Kras-compromised situation might certainly not be the sole and possibly not even the predominant reason for enhanced virulence. All the same, scientists have emphasized on Kras optimistically due to its high prevalence in various types of cancers. Incidence of Kras mutation has been found to be highest in pancreatic cancer (85%-90%) followed by colorectal (35-45%) and lung (25-30%). Reovirus, in fact has the potential not only as a therapy but also as a tool to unravel the aberrant cellular pathway leading to carcinogenicity.

UR - http://www.scopus.com/inward/record.url?scp=84871390091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871390091&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-12-0157

DO - 10.1158/1541-7786.MCR-12-0157

M3 - Article

VL - 10

SP - 1514

EP - 1525

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 12

ER -